Compare NRSN & MLCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRSN | MLCI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Israel | United States |
| Employees | 16 | 21 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 31.3M |
| IPO Year | N/A | N/A |
| Metric | NRSN | MLCI |
|---|---|---|
| Price | $0.70 | $2.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 131.3K | 27.7K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $583.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $2.68 |
| 52 Week High | $2.52 | $8.68 |
| Indicator | NRSN | MLCI |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 33.10 |
| Support Level | $0.67 | $2.68 |
| Resistance Level | $0.75 | $7.98 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 11.50 | 16.90 |
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.